Pharmasset Announces Initiation of Hepatitis Antiviral Combination Study
Posted on: Tuesday, 11 November 2008, 09:00 CST
Pharmasset, a clinical-stage pharmaceutical company, Roche and InterMune, a biotechnology company, have announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus.
The trial is said to be the first to investigate the combination of two oral antiviral molecules in the absence of interferon. The initial study will evaluate the safety and combined antiviral activity of R7227 (ITMN-191), a protease inhibitor, and R7128, a polymerase inhibitor, in 14 days of combination therapy in treatment-naive patients infected with hepatitis C virus (HCV) genotype 1.
This direct antiviral combination study represents an important first step in evaluating the therapeutic potential of an all-oral, interferon-free combination treatment for HCV, the three companies said.
Dan Welch, chairman, CEO and president of InterMune, said: "The goal is to develop a treatment regimen that is better tolerated, shorter in duration and delivers higher sustained viral response rates. We are pleased to participate in the first clinical exploration of an all-oral, direct antiviral regimen towards that goal."
Source: Datamonitor
Related Articles
- U.S. Food and Drug Administration (FDA) Approves PREZISTA(R) Once-Daily As Part of Combination Therapy for Treatment-Naive Adults With HIV-1
- Nereus Initiates Combination Clinical Trial for Solid Tumors
- Global Media Networks, Inc. Announces Biocure Med Inc. Has Obtained Confirmed Positive Results From Pre-Clinical Diabetes Treatment of Proprietary Product DiaCure(TM)
- Possible Oral Treatment for Diabetics
- B.C. Wins Showdown With Private Clinic; Clinic Won't Bill Patients
- Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients With Cardiovascular Disease
- Bird Flu Virus Found Resistant to Antiviral Drug Tamiflu in Vietnamese Patient
- Effects of Lipo-Prostaglandin E^Sub 1^ on Pulmonary Hemodynamics and Clinical Outcomes in Patients With Pulmonary Arterial Hypertension*
- Advitech Completes Recruitment for Its Second Clinical Study on Oral Treatment for Psoriasis
 |
 |
User Comments (0)
RSS Feeds